Fentiazac sodium

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H584250

CAS#: 96593-16-7 (sodium)

Description: Fentiazac, also known as BR-700, is a non-steroidal anti-inflammatory agent used to treat inflammation and pain.


Chemical Structure

img
Fentiazac sodium
CAS# 96593-16-7 (sodium)

Theoretical Analysis

Hodoodo Cat#: H584250
Name: Fentiazac sodium
CAS#: 96593-16-7 (sodium)
Chemical Formula: 17H11ClNNaO2S
Exact Mass: 329.03
Molecular Weight: 351.780
Elemental Analysis: C, 58.04; H, 3.15; Cl, 10.08; N, 3.98; Na, 6.54; O, 9.10; S, 9.11

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 85721-24-0 (calcium)   96593-16-7 (sodium)   18046-21-4 (free acid)    

Synonym: Fentiazac sodium; Fentiazac; BR-700; BR-700; BR-700; CH800; CH-800; CH 800; NSC 282191; WY-21,894; WY21,894; WY 21,894; WY-21894; WY21894; WY 21894; Norvedan; Donorest; Flogene

IUPAC/Chemical Name: 5-Thiazoleacetic acid, 4-(p-chlorophenyl)-2-phenyl-, sodium salt

InChi Key: BGPAPLSVPJLNMH-UHFFFAOYSA-M

InChi Code: InChI=1S/C17H12ClNO2S.Na/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12;/h1-9H,10H2,(H,20,21);/q;+1/p-1

SMILES Code: O=C([O-])CC1=C(C2=CC=C(Cl)C=C2)N=C(C3=CC=CC=C3)S1.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 351.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Famaey JP, Gaci O, Ginsberg F. Fentiazac in the treatment of osteoarthritis and tendinitis. Curr Med Res Opin. 1983;8(9):675-81. PubMed PMID: 6365468.

2: Nagatomi H, Ando K. Studies on the anti-inflammatory activity and ulcerogenic adverse effect of thiazole derivatives, especially 2-amino-thiazoleacetic acid derivatives. Arzneimittelforschung. 1984;34(5):599-603. PubMed PMID: 6540578.

3: Catti A. Controlled clinical study with Fentiazac suspension in painful inflammatory diseases of children. J Int Med Res. 1983;11(5):298-302. PubMed PMID: 6605890.

4: Houin G, Lapeyre C, Rochas MA, Tufenkji AE, Campistron G, Coulais Y, Akbaraly JP, Grislain L, Beck H. Pharmacokinetic study of fentiazac and its main metabolite hydroxyfentiazac in the elderly. Arzneimittelforschung. 1993 Jan;43(1):50-3. PubMed PMID: 8447848.

5: Shimura K, Oto A, Hanai Y, Watanabe S, Toda M, Asada K, Ishibashi K, Shimabukuro Y, Yokochi N, Shiramizu H, Fuse T, Saeki T, Hayakawa T. Analgesic effect of fentiazac after tooth extraction or minor oral surgery. Clin Ther. 1981;4(1):12-7. PubMed PMID: 6974045.

6: López Rosales C, Cisneros Lugo JH, Romo Enciso LJ, García Sandoval MG. [Nimesulide in the treatment of primary dysmenorrhea. Comparative clinical evaluation with mefenamic acid and fentiazac]. Ginecol Obstet Mex. 1989 Jul;57:196-201. Spanish. PubMed PMID: 2486951.

7: Ginsberg F, Famaey JP. A double-blind comparison of slow-release and standard tablet formulations of fentiazac in the treatment of patients with tendinitis and bursitis. Curr Med Res Opin. 1985;9(7):442-8. PubMed PMID: 4028807.

8: Bunde B, Deckers Y, Dequeker J. Fentiazac in rheumatoid arthritis: comparison with sulindac and long-term tolerance. Curr Med Res Opin. 1983;8(5):310-4. PubMed PMID: 6340972.

9: Thumb N, Kolarz G, Scherak O, Mayrhofer F. The efficacy and safety of fentiazac and diclofenac sodium in peri-arthritis of the shoulder: a multi-centre, double-blind comparison. J Int Med Res. 1987 Nov-Dec;15(6):327-34. PubMed PMID: 3325316.

10: López JM. Treatment of acute tendinitis and bursitis with fentiazac--a double-blind comparison with placebo. Clin Ther. 1982;5(1):79-84. PubMed PMID: 6751536.

11: Leguen MA. Single-blind clinical trial comparing use of fentiazac and paracetamol in postendodontic periodontitis. Clin Ther. 1985;7(2):145-50. PubMed PMID: 3886139.

12: Molina J. Fentiazac in acute gouty arthritis. Clin Ther. 1985;7(3):327-33. PubMed PMID: 3995528.

13: Rendina GM, Patrono D, Iansiti A. [The use of fentiazac in the therapy of primary dysmenorrhea]. Minerva Ginecol. 1982 May;34(5):395-400. Italian. PubMed PMID: 6982435.

14: Fumero S, Mondino A, Silvestri S, Zanolo G, De Marchi G, Pedrazzini S. Metabolism of fentiazac. Arzneimittelforschung. 1980;30(8):1253-6. PubMed PMID: 7192138.

15: Kweon DS, Shim CK, Lee MH. Effect of cimetidine on the pharmacokinetics of fentiazac in rats. J Pharm Sci. 1993 Sep;82(9):952-5. PubMed PMID: 8229695.

16: Fumero S, Mondino A, Silvestri S, Zanolo G, De Marchi G, Pedrazzini S. Binding of fentiazac to serum protein. Pharmacol Res Commun. 1980 Jan;12(1):41-8. PubMed PMID: 7384163.

17: Zanolo G, Giachetti C, Mondino A, Silvestri S, Bianchi E, Segre G, Gomarasca P, De Marchi G. Pharmacokinetics of fentiazac in rats and monkeys. Arzneimittelforschung. 1981;31(7):1098-104. PubMed PMID: 7196759.

18: Bex FJ, Corbin A. Cyclic response of hypophysectomized rats to ovulation induced by LHRH agonist: mediation by prostaglandins. Life Sci. 1984 Aug 27;35(9):969-79. PubMed PMID: 6433130.

19: de Menezes MR, Catanzaro-Guimarães SA. Determination of anti-inflammatory and antimitotic activities of non-steroid anti-inflammatory drugs ibuprofen, diclofenac sodium and fentiazac. Cell Mol Biol. 1985;31(6):455-61. PubMed PMID: 4075369.

20: Franklin RA, Norris R, Shepherd NW, Rhenius ST. Preliminary studies on the fate of 14C-fentiazac in man. Xenobiotica. 1984 Dec;14(12):956-60. PubMed PMID: 6531943.